vs

Side-by-side financial comparison of MEDIFAST INC (MED) and Newsmax Inc. (NMAX). Click either name above to swap in a different company.

MEDIFAST INC is the larger business by last-quarter revenue ($75.1M vs $52.2M, roughly 1.4× Newsmax Inc.). Newsmax Inc. produced more free cash flow last quarter ($1.8M vs $-6.6M).

Medifast, Inc. is an American nutrition and weight loss company based in Baltimore, Maryland. Medifast produces, distributes, and sells weight loss and health-related products through websites, multi-level marketing, telemarketing, and franchised weight loss clinics.

Newsmax Inc. is a U.S.-headquartered media and broadcasting company that offers news coverage, political commentary, opinion pieces, and lifestyle programming across cable TV, official websites, mobile apps, and streaming platforms. It mainly caters to U.S. domestic audiences, with a core focus on conservative-oriented current affairs content segments.

MED vs NMAX — Head-to-Head

Bigger by revenue
MED
MED
1.4× larger
MED
$75.1M
$52.2M
NMAX
More free cash flow
NMAX
NMAX
$8.4M more FCF
NMAX
$1.8M
$-6.6M
MED

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
MED
MED
NMAX
NMAX
Revenue
$75.1M
$52.2M
Net Profit
$-3.0M
Gross Margin
69.4%
36.7%
Operating Margin
-10.4%
-9.0%
Net Margin
-5.7%
Revenue YoY
-36.9%
Net Profit YoY
EPS (diluted)
$-1.64
$0.15

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
MED
MED
NMAX
NMAX
Q4 25
$75.1M
$52.2M
Q3 25
$89.4M
$45.3M
Q2 25
$105.6M
$46.4M
Q1 25
$115.7M
$45.3M
Q4 24
$119.0M
Q3 24
$140.2M
Q2 24
$168.6M
Q1 24
$174.7M
Net Profit
MED
MED
NMAX
NMAX
Q4 25
$-3.0M
Q3 25
$-2.3M
$-4.1M
Q2 25
$2.5M
$-75.2M
Q1 25
$-772.0K
$-17.2M
Q4 24
Q3 24
$1.1M
Q2 24
$-8.2M
Q1 24
$8.3M
Gross Margin
MED
MED
NMAX
NMAX
Q4 25
69.4%
36.7%
Q3 25
69.5%
35.3%
Q2 25
72.6%
38.0%
Q1 25
72.8%
47.8%
Q4 24
74.1%
Q3 24
75.4%
Q2 24
73.2%
Q1 24
72.8%
Operating Margin
MED
MED
NMAX
NMAX
Q4 25
-10.4%
-9.0%
Q3 25
-4.6%
-15.9%
Q2 25
-1.0%
-164.5%
Q1 25
-1.1%
-25.5%
Q4 24
0.6%
Q3 24
1.5%
Q2 24
-4.7%
Q1 24
4.5%
Net Margin
MED
MED
NMAX
NMAX
Q4 25
-5.7%
Q3 25
-2.5%
-9.1%
Q2 25
2.3%
-161.9%
Q1 25
-0.7%
-38.0%
Q4 24
Q3 24
0.8%
Q2 24
-4.8%
Q1 24
4.8%
EPS (diluted)
MED
MED
NMAX
NMAX
Q4 25
$-1.64
$0.15
Q3 25
$-0.21
$-0.03
Q2 25
$0.22
$-0.59
Q1 25
$-0.07
$-0.49
Q4 24
$0.08
Q3 24
$0.10
Q2 24
$-0.75
Q1 24
$0.76

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
MED
MED
NMAX
NMAX
Cash + ST InvestmentsLiquidity on hand
$167.3M
$20.4M
Total DebtLower is stronger
Stockholders' EquityBook value
$198.9M
$106.0M
Total Assets
$248.0M
$239.8M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
MED
MED
NMAX
NMAX
Q4 25
$167.3M
$20.4M
Q3 25
$173.5M
$14.2M
Q2 25
$162.7M
$33.8M
Q1 25
$164.6M
$126.7M
Q4 24
$162.3M
Q3 24
$170.0M
Q2 24
$163.5M
Q1 24
$156.4M
Stockholders' Equity
MED
MED
NMAX
NMAX
Q4 25
$198.9M
$106.0M
Q3 25
$214.7M
$106.0M
Q2 25
$216.0M
$106.9M
Q1 25
$211.0M
$177.4M
Q4 24
$210.1M
Q3 24
$207.3M
Q2 24
$205.3M
Q1 24
$211.0M
Total Assets
MED
MED
NMAX
NMAX
Q4 25
$248.0M
$239.8M
Q3 25
$268.2M
$233.3M
Q2 25
$269.3M
$259.8M
Q1 25
$280.0M
$278.2M
Q4 24
$284.2M
Q3 24
$291.2M
Q2 24
$293.5M
Q1 24
$302.8M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
MED
MED
NMAX
NMAX
Operating Cash FlowLast quarter
$-5.3M
$2.6M
Free Cash FlowOCF − Capex
$-6.6M
$1.8M
FCF MarginFCF / Revenue
-8.8%
3.4%
Capex IntensityCapex / Revenue
1.8%
1.7%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$1.2M
$-107.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
MED
MED
NMAX
NMAX
Q4 25
$-5.3M
$2.6M
Q3 25
$12.1M
$-68.1M
Q2 25
$-3.4M
$-23.2M
Q1 25
$3.4M
$-15.7M
Q4 24
$-4.9M
Q3 24
$9.1M
Q2 24
$13.1M
Q1 24
$7.3M
Free Cash Flow
MED
MED
NMAX
NMAX
Q4 25
$-6.6M
$1.8M
Q3 25
$10.8M
$-69.2M
Q2 25
$-4.8M
$-23.8M
Q1 25
$1.9M
$-15.8M
Q4 24
$-7.2M
Q3 24
$7.7M
Q2 24
$11.1M
Q1 24
$5.4M
FCF Margin
MED
MED
NMAX
NMAX
Q4 25
-8.8%
3.4%
Q3 25
12.0%
-152.9%
Q2 25
-4.5%
-51.3%
Q1 25
1.6%
-34.9%
Q4 24
-6.1%
Q3 24
5.5%
Q2 24
6.6%
Q1 24
3.1%
Capex Intensity
MED
MED
NMAX
NMAX
Q4 25
1.8%
1.7%
Q3 25
1.5%
2.4%
Q2 25
1.3%
1.3%
Q1 25
1.3%
0.2%
Q4 24
1.9%
Q3 24
1.0%
Q2 24
1.1%
Q1 24
1.1%
Cash Conversion
MED
MED
NMAX
NMAX
Q4 25
Q3 25
Q2 25
-1.36×
Q1 25
Q4 24
Q3 24
8.04×
Q2 24
Q1 24
0.88×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

MED
MED

Segment breakdown not available.

NMAX
NMAX

Advertising$33.9M65%
Affiliate Fee$8.3M16%
Subscription And Circulation$6.2M12%
Products$2.6M5%
Supplement Sales$1.1M2%

Related Comparisons